Ionis Pharmaceuticals, Inc. (0JDI.L)
USD 25.91
(1.15%)
USD 25.91
(1.15%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 2.99 Billion USD | 18.0% |
| 2022 | 2.53 Billion USD | -2.99% |
| 2021 | 2.61 Billion USD | 9.29% |
| 2020 | 2.39 Billion USD | -26.07% |
| 2019 | 3.23 Billion USD | 21.19% |
| 2018 | 2.66 Billion USD | 101.8% |
| 2017 | 1.32 Billion USD | 44.88% |
| 2016 | 912.46 Million USD | -4.56% |
| 2015 | 956.1 Million USD | 0.03% |
| 2014 | 955.8 Million USD | 12.83% |
| 2013 | 847.15 Million USD | 55.25% |
| 2012 | 545.68 Million USD | 12.54% |
| 2011 | 484.89 Million USD | -11.91% |
| 2010 | 550.47 Million USD | -16.24% |
| 2009 | 657.18 Million USD | 14.46% |
| 2008 | 574.15 Million USD | 121.8% |
| 2007 | 258.85 Million USD | 1.15% |
| 2006 | 255.9 Million USD | 53.82% |
| 2005 | 166.37 Million USD | -20.18% |
| 2004 | 208.42 Million USD | -37.77% |
| 2003 | 334.94 Million USD | -23.65% |
| 2002 | 438.68 Million USD | 5.18% |
| 2001 | 417.06 Million USD | 127.58% |
| 2000 | 183.25 Million USD | 77.75% |
| 1999 | 103.1 Million USD | 7.28% |
| 1998 | 96.1 Million USD | -18.49% |
| 1997 | 117.9 Million USD | 16.39% |
| 1996 | 101.3 Million USD | 1.71% |
| 1995 | 99.6 Million USD | 49.55% |
| 1994 | 66.6 Million USD | -15.48% |
| 1993 | 78.8 Million USD | 41.98% |
| 1992 | 55.5 Million USD | -24.59% |
| 1991 | 73.6 Million USD | 1611.63% |
| 1990 | 4.3 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 2.69 Billion USD | -2.63% |
| 2024 Q1 | 2.76 Billion USD | -7.56% |
| 2023 Q2 | 2.97 Billion USD | 2.98% |
| 2023 FY | 2.99 Billion USD | 18.0% |
| 2023 Q3 | 2.93 Billion USD | -1.25% |
| 2023 Q4 | 2.99 Billion USD | 1.91% |
| 2023 Q1 | 2.88 Billion USD | 13.85% |
| 2022 Q2 | 2.45 Billion USD | -2.5% |
| 2022 FY | 2.53 Billion USD | -2.99% |
| 2022 Q1 | 2.51 Billion USD | -3.56% |
| 2022 Q4 | 2.53 Billion USD | 4.63% |
| 2022 Q3 | 2.42 Billion USD | -1.39% |
| 2021 FY | 2.61 Billion USD | 9.29% |
| 2021 Q1 | 2.24 Billion USD | -5.92% |
| 2021 Q4 | 2.61 Billion USD | 8.16% |
| 2021 Q2 | 2.49 Billion USD | 11.05% |
| 2021 Q3 | 2.41 Billion USD | -3.29% |
| 2020 Q4 | 2.39 Billion USD | -22.8% |
| 2020 Q1 | 3.09 Billion USD | -4.39% |
| 2020 FY | 2.39 Billion USD | -26.07% |
| 2020 Q2 | 3.07 Billion USD | -0.39% |
| 2020 Q3 | 3.09 Billion USD | 0.54% |
| 2019 Q2 | 2.87 Billion USD | 1.48% |
| 2019 Q3 | 2.89 Billion USD | 0.59% |
| 2019 Q4 | 3.23 Billion USD | 11.68% |
| 2019 FY | 3.23 Billion USD | 21.19% |
| 2019 Q1 | 2.83 Billion USD | 6.3% |
| 2018 Q3 | 2.24 Billion USD | 0.03% |
| 2018 Q4 | 2.66 Billion USD | 18.68% |
| 2018 FY | 2.66 Billion USD | 101.8% |
| 2018 Q1 | 1.29 Billion USD | -1.7% |
| 2018 Q2 | 2.24 Billion USD | 72.93% |
| 2017 Q2 | 1.09 Billion USD | 0.63% |
| 2017 Q3 | 1.25 Billion USD | 14.83% |
| 2017 Q4 | 1.32 Billion USD | 5.55% |
| 2017 FY | 1.32 Billion USD | 44.88% |
| 2017 Q1 | 1.08 Billion USD | 18.8% |
| 2016 Q4 | 912.46 Million USD | 8.17% |
| 2016 FY | 912.46 Million USD | -4.56% |
| 2016 Q1 | 875.81 Million USD | -8.4% |
| 2016 Q2 | 811.1 Million USD | -7.39% |
| 2016 Q3 | 843.58 Million USD | 4.0% |
| 2015 Q3 | 988 Million USD | 1.2% |
| 2015 Q4 | 956.1 Million USD | -3.23% |
| 2015 Q1 | 955.43 Million USD | -0.04% |
| 2015 FY | 956.1 Million USD | 0.03% |
| 2015 Q2 | 976.25 Million USD | 2.18% |
| 2014 Q3 | 793.8 Million USD | -2.93% |
| 2014 Q2 | 817.77 Million USD | -2.02% |
| 2014 Q1 | 834.61 Million USD | -1.48% |
| 2014 FY | 955.8 Million USD | 12.83% |
| 2014 Q4 | 955.8 Million USD | 20.41% |
| 2013 Q4 | 847.15 Million USD | -3.94% |
| 2013 Q2 | 788.65 Million USD | 42.62% |
| 2013 Q1 | 552.96 Million USD | 1.33% |
| 2013 FY | 847.15 Million USD | 55.25% |
| 2013 Q3 | 881.91 Million USD | 11.83% |
| 2012 Q1 | 470.8 Million USD | -2.91% |
| 2012 Q3 | 485.68 Million USD | 2.81% |
| 2012 Q4 | 545.68 Million USD | 12.35% |
| 2012 Q2 | 472.39 Million USD | 0.34% |
| 2012 FY | 545.68 Million USD | 12.54% |
| 2011 Q1 | 505.94 Million USD | -8.09% |
| 2011 FY | 484.89 Million USD | -11.91% |
| 2011 Q3 | 505.78 Million USD | -4.49% |
| 2011 Q2 | 529.57 Million USD | 4.67% |
| 2011 Q4 | 484.89 Million USD | -4.13% |
| 2010 Q3 | 575.85 Million USD | -5.03% |
| 2010 Q2 | 606.35 Million USD | 1.11% |
| 2010 Q1 | 599.72 Million USD | -8.74% |
| 2010 FY | 550.47 Million USD | -16.24% |
| 2010 Q4 | 550.47 Million USD | -4.41% |
| 2009 Q3 | 680.57 Million USD | -4.03% |
| 2009 Q1 | 724.5 Million USD | 26.19% |
| 2009 FY | 657.18 Million USD | 14.46% |
| 2009 Q2 | 709.16 Million USD | -2.12% |
| 2009 Q4 | 657.18 Million USD | -3.44% |
| 2008 Q3 | 584.69 Million USD | -4.05% |
| 2008 Q4 | 574.15 Million USD | -1.8% |
| 2008 FY | 574.15 Million USD | 121.8% |
| 2008 Q1 | 405.42 Million USD | 56.62% |
| 2008 Q2 | 609.39 Million USD | 50.31% |
| 2007 FY | 258.85 Million USD | 1.15% |
| 2007 Q1 | 349.9 Million USD | 36.73% |
| 2007 Q2 | 263.25 Million USD | -24.76% |
| 2007 Q3 | 213 Million USD | -19.09% |
| 2007 Q4 | 258.85 Million USD | 21.53% |
| 2006 FY | 255.9 Million USD | 53.82% |
| 2006 Q1 | 150.63 Million USD | -9.46% |
| 2006 Q2 | 201.91 Million USD | 34.04% |
| 2006 Q3 | 187.76 Million USD | -7.01% |
| 2006 Q4 | 255.9 Million USD | 36.29% |
| 2005 Q4 | 166.37 Million USD | -6.21% |
| 2005 Q3 | 177.38 Million USD | 21.06% |
| 2005 Q2 | 146.52 Million USD | -16.58% |
| 2005 Q1 | 175.64 Million USD | -15.73% |
| 2005 FY | 166.37 Million USD | -20.18% |
| 2004 Q4 | 208.42 Million USD | -18.35% |
| 2004 FY | 208.42 Million USD | -37.77% |
| 2004 Q3 | 255.27 Million USD | -8.82% |
| 2004 Q2 | 279.96 Million USD | -10.48% |
| 2004 Q1 | 312.72 Million USD | -6.63% |
| 2003 Q2 | 370.85 Million USD | -10.66% |
| 2003 Q3 | 353.54 Million USD | -4.67% |
| 2003 FY | 334.94 Million USD | -23.65% |
| 2003 Q1 | 415.09 Million USD | -5.38% |
| 2003 Q4 | 334.94 Million USD | -5.26% |
| 2002 Q2 | 443.22 Million USD | 10.9% |
| 2002 Q1 | 399.66 Million USD | -4.17% |
| 2002 FY | 438.68 Million USD | 5.18% |
| 2002 Q4 | 438.68 Million USD | 3.34% |
| 2002 Q3 | 424.52 Million USD | -4.22% |
| 2001 Q1 | 163.36 Million USD | -10.85% |
| 2001 Q4 | 417.06 Million USD | 41.66% |
| 2001 Q3 | 294.41 Million USD | 57.0% |
| 2001 Q2 | 187.52 Million USD | 14.79% |
| 2001 FY | 417.06 Million USD | 127.58% |
| 2000 Q3 | 176.57 Million USD | -0.25% |
| 2000 FY | 183.25 Million USD | 77.75% |
| 2000 Q2 | 177.02 Million USD | 16.58% |
| 2000 Q1 | 151.84 Million USD | 47.28% |
| 2000 Q4 | 183.25 Million USD | 3.78% |
| 1999 Q1 | 82.9 Million USD | -13.74% |
| 1999 Q4 | 103.1 Million USD | 9.56% |
| 1999 FY | 103.1 Million USD | 7.28% |
| 1999 Q3 | 94.1 Million USD | -1.26% |
| 1999 Q2 | 95.3 Million USD | 14.96% |
| 1998 FY | 96.1 Million USD | -18.49% |
| 1998 Q4 | 96.1 Million USD | -10.02% |
| 1998 Q3 | 106.8 Million USD | -9.18% |
| 1998 Q2 | 117.6 Million USD | 16.09% |
| 1998 Q1 | 101.3 Million USD | -14.08% |
| 1997 Q3 | 97.3 Million USD | -1.82% |
| 1997 FY | 117.9 Million USD | 16.39% |
| 1997 Q1 | 97.8 Million USD | -3.46% |
| 1997 Q4 | 117.9 Million USD | 21.17% |
| 1997 Q2 | 99.1 Million USD | 1.33% |
| 1996 FY | 101.3 Million USD | 1.71% |
| 1996 Q4 | 101.3 Million USD | 19.32% |
| 1996 Q1 | 98.7 Million USD | -0.9% |
| 1996 Q2 | 91.6 Million USD | -7.19% |
| 1996 Q3 | 84.9 Million USD | -7.31% |
| 1995 Q3 | 80.5 Million USD | 38.08% |
| 1995 Q1 | 60.2 Million USD | -9.61% |
| 1995 Q4 | 99.6 Million USD | 23.73% |
| 1995 FY | 99.6 Million USD | 49.55% |
| 1995 Q2 | 58.3 Million USD | -3.16% |
| 1994 FY | 66.6 Million USD | -15.48% |
| 1994 Q1 | 80.3 Million USD | 1.9% |
| 1994 Q3 | 71.3 Million USD | -3.52% |
| 1994 Q4 | 66.6 Million USD | -6.59% |
| 1994 Q2 | 73.9 Million USD | -7.97% |
| 1993 FY | 78.8 Million USD | 41.98% |
| 1993 Q1 | 67.2 Million USD | 21.08% |
| 1993 Q2 | 62.4 Million USD | -7.14% |
| 1993 Q3 | 60.4 Million USD | -3.21% |
| 1993 Q4 | 78.8 Million USD | 30.46% |
| 1992 FY | 55.5 Million USD | -24.59% |
| 1992 Q4 | 55.5 Million USD | -8.57% |
| 1992 Q1 | 68.5 Million USD | -6.93% |
| 1992 Q2 | 65 Million USD | -5.11% |
| 1992 Q3 | 60.7 Million USD | -6.62% |
| 1991 Q1 | 19 Million USD | 341.86% |
| 1991 Q4 | 73.6 Million USD | 82.18% |
| 1991 FY | 73.6 Million USD | 1611.63% |
| 1991 Q3 | 40.4 Million USD | -7.34% |
| 1991 Q2 | 43.6 Million USD | 129.47% |
| 1990 Q4 | 4.3 Million USD | 0.0% |
| 1990 FY | 4.3 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| uniQure N.V. | 831.68 Million USD | -259.518% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | -219.071% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | -284.387% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | -1706.646% |
| bluebird bio, Inc. | 619.16 Million USD | -382.923% |
| Cara Therapeutics, Inc. | 125.84 Million USD | -2276.015% |
| Imunon, Inc. | 21.91 Million USD | -13542.041% |
| Editas Medicine, Inc. | 499.15 Million USD | -499.029% |
| IQVIA Holdings Inc. | 26.68 Billion USD | 88.793% |
| Mettler-Toledo International Inc. | 3.35 Billion USD | 10.892% |
| Myriad Genetics, Inc. | 1.19 Billion USD | -149.443% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | 8.037% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | -112.216% |
| Verastem, Inc. | 149.71 Million USD | -1897.136% |
| Walgreens Boots Alliance, Inc. | 81.03 Billion USD | 96.31% |
| Waters Corporation | 4.62 Billion USD | 35.376% |
| Thermo Fisher Scientific Inc. | 98.72 Billion USD | 96.971% |
| Biogen Inc. | 26.84 Billion USD | 88.862% |
| Nektar Therapeutics | 398.03 Million USD | -651.212% |
| Perrigo Company plc | 10.8 Billion USD | 72.337% |
| Dynavax Technologies Corporation | 997.09 Million USD | -199.878% |
| Illumina, Inc. | 10.11 Billion USD | 70.428% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -10475.942% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | -283.17% |
| Heron Therapeutics, Inc. | 222.5 Million USD | -1243.816% |
| Unity Biotechnology, Inc. | 65.69 Million USD | -4451.792% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 56.296% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | -1708.657% |
| Evolus, Inc. | 188.99 Million USD | -1482.065% |
| Adicet Bio, Inc. | 207.29 Million USD | -1342.424% |
| Aclaris Therapeutics, Inc. | 197.4 Million USD | -1414.689% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 90.961% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | -1352.93% |
| FibroGen, Inc. | 423.52 Million USD | -605.99% |
| Agilent Technologies, Inc. | 10.76 Billion USD | 72.219% |
| OPKO Health, Inc. | 2.01 Billion USD | -48.634% |
| Homology Medicines, Inc. | 47.05 Million USD | -6254.149% |
| Geron Corporation | 394.07 Million USD | -658.755% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | 21.928% |
| Exelixis, Inc. | 2.94 Billion USD | -1.622% |
| Viking Therapeutics, Inc. | 368.49 Million USD | -711.439% |
| Anavex Life Sciences Corp. | 154.38 Million USD | -1836.751% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | -129.833% |
| Zoetis Inc. | 14.28 Billion USD | 79.07% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | -408.312% |
| Abeona Therapeutics Inc. | 64 Million USD | -4571.842% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 86.845% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | -5244.281% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | 8.409% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | -381.093% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | -72.51% |
| Blueprint Medicines Corporation | 1.04 Billion USD | -184.972% |
| Insmed Incorporated | 1.32 Billion USD | -124.845% |
| TG Therapeutics, Inc. | 329.58 Million USD | -807.218% |
| Incyte Corporation | 6.78 Billion USD | 55.912% |
| Emergent BioSolutions Inc. | 1.83 Billion USD | -62.956% |